ArticleOxidative medicine and cellular longevity2020
Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- The desulfinylation enzyme sulfiredoxin-1 attenuates HSC activation and liver fibrosis by modulating the PTPN12-NLRP3 axis.Hepatology (Baltimore, Md.) · 2025Article
- SLIT/ROBO Pathway and Prostate Cancer: Gene and Protein Expression and Their Prognostic Values.International journal of molecular sciences · 2025Article
- CRL3Nature communications · 2024Article
- Antioxidative stress protein SRXN1 can be used as a radiotherapy prognostic marker for prostate cancer.BMC urology · 2023Article
- Bacterial RNA virus MS2 exposure increases the expression of cancer progression genes in the LNCaP prostate cancer cell line.Oncology letters · 2023Article
- Prostate Cancer Secretome and Membrane Proteome fromInternational journal of molecular sciences · 2022Article
- Apigenin Induced Apoptosis by Downregulating Sulfiredoxin Expression in Cutaneous Squamous Cell Carcinoma.Oxidative medicine and cellular longevity · 2022Article
- Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma.Cancer cell international · 2021Article
- Article
- Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer.International journal of molecular sciences · 2021Article
- Sulfiredoxin-1 attenuates injury and inflammation in acute pancreatitis through the ROS/ER stress/Cathepsin B axis.Cell death & disease · 2021Article
- Hyperoxidation of Peroxiredoxins and Effects on Physiology ofAntioxidants (Basel, Switzerland) · 2021Article
- Sulfiredoxin-1 is a promising novel prognostic biomarker for hepatocellular carcinoma.Cancer medicine · 2020Article
- Targeting the Redox Landscape in Cancer Therapy.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of prostate cancer (PCa) is increasing, and it is currently the second most frequent cause of death by cancer in men. Despite advancements in cancer therapies, new therapeutic approaches are still needed for treatment-refractory advanced metastatic PCa. Cross-species analysis presents a robust strategy for the discovery of new potential therapeutic targets. This strategy involves the integration of genomic data from genetically engineered mouse models (GEMMs) and human PCa datasets. Considering the role of antioxidant pathways in tumor initiation and progression, we searched oxidative stress-related genes for a potential therapeutic target for PCa. First, we analyzed RNA-sequencing data from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.